Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Oxford’s Ebola vaccine recommended for deployment against Uganda outbreak

A vaccine developed by the Oxford Vaccine Group’s Prof Teresa Lambe and supported in clinical trials and manufacture scale-up by researchers from the Jenner Institute (Nuffield Department of Medicine) has been recommended for inclusion in a ring vaccination trial to combat a Sudan ebolavirus outbreak in Uganda.

An artist's impression of an Ebolavirus

A consortium set up to respond to the outbreak, including CEPI, Gavi, the World Health Organization (WHO) and Ugandan public health authorities, have outlined a range of measures.

They include the ring vaccination trial that will deploy candidate vaccines, including the University of Oxford’s ChAdOx1 biEBOV jab, against Sudan ebolavirus which is causing an ongoing outbreak in Uganda. The aim of the trial is to minimise hospitalisations and deaths. There are currently no licensed vaccines against Sudan ebolavirus.

Oxford’s vaccine has been designed to generate an immune response against two species, Ebola virus and Sudan ebolavirus, and is based on the ChAdOx1 virus, a weakened version of a common cold virus (adenovirus) that has been genetically modified so that it is impossible for it to replicate in humans. This vector has been previously used successfully in the ChAdOx1 nCoV-19 vaccine – or the Oxford-AstraZeneca COVID-19 vaccine.

Read the full story on the University of Oxford webpage

Similar stories

Exceptional early-career researchers awarded 2026 European Research Council Starting Grants

Four University of Oxford researchers have been awarded prestigious European Research Council (ERC) Starting Grants, each worth €1.5 million for a period of up to five year

How body fat is stored across organs may reveal hidden health risks, study suggests

Researchers from the Nuffield Department of Population Health and the University of Oxford’s Big Data Institute have contributed to a new study showing that how fat accumulates in the body is just as important for identifying different health risks as a person’s overall weight.

Four Oxford researchers recognised in the 2026 Royal Society Awards

The annual Royal Society Awards recognise outstanding contributions to scientific discovery, public engagement and research culture. Of the 27 awards for 2025-26, announced today, four honour Oxford University researchers.

New shingles vaccine linked to lower risk of coronary heart disease, stroke and heart failure – major study indicates

The shingles vaccine currently in use, called ‘Shingrix’, is associated with a reduced risk of cardiovascular events – including heart attacks, heart failure and stroke – compared to the previous shingles vaccine, according to a major new study published in Nature Medicine.

Vapes help more people quit smoking than other methods, Oxford-led Cochrane review finds

An updated Cochrane review led by Oxford researchers finds nicotine e-cigarettes help more people quit smoking than nicotine patches and gum, behavioural support or no support. The living review now includes 80 trials and nearly 30,000 participants.

Brain imaging study reveals how we decide whether we are in control

A brain imaging and stimulation study led by the University of Oxford has identified the brain mechanisms that help us work out whether the consequences we experience are caused by our own actions or by circumstances beyond our control.